Forma Therapeutics Holdings, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015118 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $395.9M $421.4M
YoY Change -26.08% -23.49%
Cash & Equivalents $75.14M $74.42M
Short-Term Investments $320.8M $346.9M
Other Short-Term Assets $15.17M $11.42M
YoY Change 112.78% 40.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $426.4M $446.5M
YoY Change -23.57% -22.19%
LONG-TERM ASSETS
Property, Plant & Equipment $13.64M $13.55M
YoY Change 928.28% 854.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $19.99M
YoY Change -100.0% -62.29%
Other Assets $12.84M $12.82M
YoY Change -14.56% -14.55%
Total Long-Term Assets $48.72M $67.97M
YoY Change -12.12% -10.91%
TOTAL ASSETS
Total Short-Term Assets $426.4M $446.5M
Total Long-Term Assets $48.72M $67.97M
Total Assets $475.2M $514.5M
YoY Change -22.53% -20.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.040M $2.044M
YoY Change -39.39% -29.52%
Accrued Expenses $25.05M $19.09M
YoY Change 3.98% -28.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.46M $26.34M
YoY Change 7.6% -7.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.21M $26.97M
YoY Change 846.87% 418.6%
Total Long-Term Liabilities $27.21M $26.97M
YoY Change 846.87% 418.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.46M $26.34M
Total Long-Term Liabilities $27.21M $26.97M
Total Liabilities $60.68M $53.30M
YoY Change 78.6% 57.7%
SHAREHOLDERS EQUITY
Retained Earnings -$327.1M -$274.5M
YoY Change 138.84%
Common Stock $741.6M $735.7M
YoY Change 3.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $414.5M $461.2M
YoY Change
Total Liabilities & Shareholders Equity $475.2M $514.5M
YoY Change -22.53% -20.87%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
fmtx Right Of Use Asset Recognized Upon Adoption Of Operating Lease
RightOfUseAssetRecognizedUponAdoptionOfOperatingLease
fmtx Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
fmtx Operating Lease Right Of Use Asset Obtained
OperatingLeaseRightOfUseAssetObtained
dei Entity Central Index Key
EntityCentralIndexKey
0001538927
fmtx Payment Of Deferred Offering Cost
PaymentOfDeferredOfferingCost
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39333
dei Entity Registrant Name
EntityRegistrantName
Forma Therapeutics Holdings, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1657129
dei Entity Address Address Line1
EntityAddressAddressLine1
300 North Beacon Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 501
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
679-1970
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
FMTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
183000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12837000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12612000
CY2022Q2 us-gaap Assets
Assets
475169000
CY2021Q4 us-gaap Assets
Assets
561061000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3040000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
741555000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4145000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25046000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25748000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5335000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5125000
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
43000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
70000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
33464000
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47852557
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75136000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77421000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
320767000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728683000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327110000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
386805000
CY2022Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
12054000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
11988000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18489000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
425000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
426446000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230374000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414492000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
486401000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13635000
fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
-500000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Liabilities
Liabilities
60677000
CY2021Q4 us-gaap Liabilities
Liabilities
62705000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
-0
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26047000
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22251000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1061000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22074000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35088000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27213000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27617000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47838797
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47411356
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47834542
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47398238
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
47000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
475169000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
561061000
CY2022Q2 us-gaap Revenues
Revenues
0
CY2021Q2 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39059000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31587000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70332000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57930000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13939000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12471000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27075000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22338000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
52998000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
44058000
us-gaap Operating Expenses
OperatingExpenses
97407000
us-gaap Operating Expenses
OperatingExpenses
80268000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-52998000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44058000
us-gaap Operating Income Loss
OperatingIncomeLoss
-97407000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80268000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
599000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
309000
us-gaap Investment Income Interest
InvestmentIncomeInterest
888000
us-gaap Investment Income Interest
InvestmentIncomeInterest
571000
CY2022Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-192000
CY2021Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
272000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-227000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
268000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
407000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
581000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
661000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
839000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52591000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43477000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96746000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79429000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
116000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52578000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43585000
us-gaap Net Income Loss
NetIncomeLoss
-96736000
us-gaap Net Income Loss
NetIncomeLoss
-79545000
CY2022Q2 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-52578000
CY2021Q2 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-43585000
fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-96736000
fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-79545000
CY2022Q2 fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-1.10
CY2021Q2 fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.92
fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-2.03
fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-1.68
CY2022Q2 fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47805493
CY2021Q2 fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47339464
fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47684236
fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47317361
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3848000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35960000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
616465000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6423000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43585000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
579395000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
741000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6254000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-44158000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
461193000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5789000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52578000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414492000
us-gaap Profit Loss
ProfitLoss
-96736000
us-gaap Profit Loss
ProfitLoss
-79545000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1353000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
360000
fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
555000
fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
642000
fmtx Gain Loss On Lease Modification
GainLossOnLeaseModification
0
fmtx Gain Loss On Lease Modification
GainLossOnLeaseModification
-287000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
12043000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
10271000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
165000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-761000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
17000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
66000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1207000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8328000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2180000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2555000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1082000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
721000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-706000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2117000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-27000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-189000
fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-900000
fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-882000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94059000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73776000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
209581000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
397222000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
301831000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
239440000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
91189000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157965000
fmtx Payment Of Deferred Offering Cost
PaymentOfDeferredOfferingCost
-206000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
829000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
623000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-75000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2247000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-231816000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79538000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77291000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53343000
fmtx Right Of Use Asset Recognized Upon Adoption Of Operating Lease
RightOfUseAssetRecognizedUponAdoptionOfOperatingLease
7478000
fmtx Operating Lease Right Of Use Asset Obtained
OperatingLeaseRightOfUseAssetObtained
1115000
fmtx Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
4000
CY2020Q4 fmtx Follow On Public Offering Price Per Share
FollowOnPublicOfferingPricePerShare
45.25
CY2020Q4 fmtx Proceeds From Follow On Offering After Deducting Expenses
ProceedsFromFollowOnOfferingAfterDeductingExpenses
258600000
CY2021Q3 fmtx Aggregate Amount Of Issuance And Offering Cost
AggregateAmountOfIssuanceAndOfferingCost
200000000.0
CY2021Q3 fmtx Common Stock Under The2021 Shelf
CommonStockUnderThe2021Shelf
150000000.0
CY2021Q3 fmtx Sales Agent Cash Commissions
SalesAgentCashCommissions
0.030
CY2022Q2 fmtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
395900000
fmtx Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
90 days or less
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75136000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50873000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
2155000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
2470000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77291000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53343000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
390824000
CY2022Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
320767000
CY2022Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
30000
CY2022Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
1831000
CY2022Q2 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
318966000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
412852000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
204000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
412686000
CY2022Q2 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
293400000
CY2021Q4 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
219300000
CY2022Q2 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
10688000
CY2021Q4 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
5559000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4483000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3549000
CY2022Q2 us-gaap Other Receivables
OtherReceivables
3318000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
1079000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18489000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19540000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18696000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5905000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4769000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13635000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2022Q2 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
12513000
CY2021Q4 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
11001000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6991000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8508000
CY2022Q2 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
2853000
CY2021Q4 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
3804000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1071000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
971000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1618000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1464000
CY2022Q2 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
25046000
CY2021Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
25748000
CY2022Q2 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2021Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3767000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6587987
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.44
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12110467
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5789000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6423000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12043000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10271000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5789000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6423000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12043000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10271000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5942569
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.12
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33891000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1030190
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
158804
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
225968
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.28
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6587987
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5833000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3156390
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5833000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0296
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0103
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0096
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.804
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.774
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.799
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000

Files In Submission

Name View Source Status
0000950170-22-015118-index-headers.html Edgar Link pending
0000950170-22-015118-index.html Edgar Link pending
0000950170-22-015118.txt Edgar Link pending
0000950170-22-015118-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fmtx-20220630.htm Edgar Link pending
fmtx-20220630.xsd Edgar Link pending
fmtx-20220630_cal.xml Edgar Link unprocessable
fmtx-20220630_def.xml Edgar Link unprocessable
fmtx-20220630_htm.xml Edgar Link completed
fmtx-20220630_lab.xml Edgar Link unprocessable
fmtx-20220630_pre.xml Edgar Link unprocessable
fmtx-ex10_1.htm Edgar Link pending
fmtx-ex31_1.htm Edgar Link pending
fmtx-ex31_2.htm Edgar Link pending
fmtx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending